Garcia-Manero, G., Almeida, A., Giagounidis, A., Platzbecker, U., Garcia, R., Voso, M. T., . . . Santini, V. (2016). Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: A randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia. BMC Hematol.
Citação norma ChicagoGarcia-Manero, Guillermo, et al. "Design and Rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) Trial: A Randomized Phase 3 Study of CC-486 (oral Azacitidine) Plus Best Supportive Care Vs Placebo Plus Best Supportive Care in Patients With IPSS Lower-risk Myelodysplastic Syndromes and Poor Prognosis Due to Red Blood Cell Transfusion–dependent Anemia and Thrombocytopenia." BMC Hematol 2016.
MLA citiranjeGarcia-Manero, Guillermo, et al. "Design and Rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) Trial: A Randomized Phase 3 Study of CC-486 (oral Azacitidine) Plus Best Supportive Care Vs Placebo Plus Best Supportive Care in Patients With IPSS Lower-risk Myelodysplastic Syndromes and Poor Prognosis Due to Red Blood Cell Transfusion–dependent Anemia and Thrombocytopenia." BMC Hematol 2016.